U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 3 of 3 results

Status:
US Approved Rx (2021)
First approved in 2021

Class (Stereo):
CHEMICAL (ACHIRAL)



Tepotinib is an investigational small molecule inhibitor of the c-Met receptor tyrosine kinase. Alterations of the c-Met signaling pathway are found in various cancer types and correlate with aggressive tumor behavior and poor clinical prognosis. Tep...
Status:
US Approved Rx (2021)
First approved in 2021

Class (Stereo):
CHEMICAL (ACHIRAL)



Tepotinib is an investigational small molecule inhibitor of the c-Met receptor tyrosine kinase. Alterations of the c-Met signaling pathway are found in various cancer types and correlate with aggressive tumor behavior and poor clinical prognosis. Tep...
Status:
US Approved Rx (2021)
First approved in 2021

Class (Stereo):
CHEMICAL (ACHIRAL)



Tepotinib is an investigational small molecule inhibitor of the c-Met receptor tyrosine kinase. Alterations of the c-Met signaling pathway are found in various cancer types and correlate with aggressive tumor behavior and poor clinical prognosis. Tep...